ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS-I LIKE PROTEIN (OMCP) FOR TREATMENT OF AUTOIMMUNE DISEASE
Compositions and methods for treatment of autoimmune and inflammatory conditions which include Orthopox Major Histocompatibility complex (MHC) class I-like protein (OMCP) or a variant thereof.
1 . A method for treating an autoimmune or inflammatory disease in a subject diagnosed with or suffering from the autoimmune or inflammatory disease, comprising administering to the subject a therapeutically effective amount of a composition, wherein the composition comprises Orthopoxvirus Major Histocompatibility complex (MHC) class I-like protein (OMCP) or a variant thereof.
2 . The method of claim 1 , wherein the OMCP or variant thereof comprises an amino acid sequence that has at least 80% sequence identity to any one of SEQ ID NOs: 1-3.
3 - 7 . (canceled)
8 . The method of claim 1 , wherein the OMCP or variant thereof comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
9 .- 10 . (canceled)
11 . The method of claim 1 , wherein the OMCP or variant thereof has a binding affinity for human NKG2D of from about 0.1 nM to about 1000 nM.
12 .- 13 . (canceled)
14 . The method of claim 1 , wherein the OMCP or variant thereof is not linked to a cytokine.
15 .- 17 . (canceled)
18 . The method of claim 1 , wherein the OMCP or variant thereof further comprises polyethylene glycol (PEG), and wherein the PEG is selected from the group consisting of PEG-10K, PEG-20K and PEG-40K.
19 .- 33 . (canceled)
34 . The method of claim 1 , wherein the OMCP or variant thereof comprises N-linked glycans.
35 .- 58 . (canceled)
59 . The method of claim 1 , wherein the OMCP or variant thereof is linked to a human immunoglobin IgG Fc chain.
60 .- 107 . (canceled)
108 . The method of claim 1 , wherein the OMCP or variant thereof is present in the composition in a form selected from the group consisting of encapsulated in a liposome or micelle, in a miroemulsion, or linked to a dendrimer.
109 .- 205 . (canceled)
206 . The method of claim 1 , wherein the composition further comprises an excipient, and wherein the excipient is selected from the group consisting of a diluent, a binder, a filler, a buffering agent, a pH modifying agent, a disintegrant, a dispersant, a preservative, a lubricant, taste-masking agent, a flavoring agent, or a coloring agent.
207 . (canceled)
208 . The method of claim 206 , wherein the excipient is present in the composition in an amount from about 1% to about 99% by weight.
209 . The method of claim 1 , wherein the step of administering is by parenteral administration, topical administration, injection, or oral administration.
210 .- 221 . (canceled)
222 . The method of claim 1 , wherein the autoimmune or inflammatory disease is selected from the group consisting of intestinal inflammation, type I diabetes, multiple sclerosis, rheumatoid arthritis, and chronic obstructive pulmonary disease (COPD).
223 . The method of claim 1 , wherein the OMCP or variant thereof is the only pharmaceutically active component in the composition.
224 . The method of claim 1 , wherein the OMCP or variant thereof is not linked to or conjugated to any other peptide.
225 . The method of claim 1 , wherein the OMCP or variant thereof is not linked to or conjugated to an antibody or fragment thereof.
226 . The method of claim 1 , wherein the OMCP or variant thereof is not linked to or conjugated to any other therapeutic moiety.
227 . The method of claim 1 , wherein the OMCP or variant thereof is not linked to or conjugated to a targeting moiety.
228 . The method of claim 1 , wherein the composition further comprises another therapeutic compound.